The candidate now entering phase-three trials targets the influenza virus's conserved stalk rather than its mutable head — the approach immunologists have chased for four decades. Earlier-phase data showed durable antibody responses across every strain family tested, including avian lineages that seasonal vaccines miss entirely.
The trial's design is itself a milestone: simultaneous enrolment across six continents, with sites selected to capture the widest genetic and epidemiological diversity ever assembled for a respiratory vaccine study. Health agencies in the global south negotiated manufacturing commitments into the protocol — a lesson institutionalised from the pandemic era.
Researchers are disciplined about expectations; stalk-targeting candidates have disappointed before, and efficacy against infection may prove lower than efficacy against severe disease. But even the conservative scenario — a vaccine reformulated once a decade instead of annually — would rank among the most consequential public-health advances of the century.